Effect of GLP-1 Receptor Agonists on Post-Ablation Atrial Fibrillation Recurrence: A Meta‑Analysis
Abstract
Background: Among patients undergoing catheter ablation for atrial fibrillation (AF), it remains uncertain whether peri- or post-ablation use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduces AF recurrence.
Objectives: We conducted a meta-analysis of observational studies and randomized controlled trials comparing GLP-1 RA therapy versus no GLP-1 RA use on AF recurrence following ablation.
Methods: We systematically searched PubMed, Scopus, Web of Science, and Embase for adult randomized and observational studies. Random-effects models generated risk ratios (RRs), and heterogeneity was assessed via I2. Time-to-event outcomes were synthesized using reconstructed individual patient data from Kaplan-Meier curves.
Results: Six studies met the inclusion criteria, with four contributing data for Kaplan-Meier curve reconstruction and five included in the hazard ratio (HR) meta-analysis. Across four studies (n = 695; GLP-1 RA = 295; control = 400), pooled Kaplan-Meier curves showed a lower risk of AF recurrence with GLP-1 RA therapy (HR 0.53, 95% confidence interval [CI]: 0.38-0.72), with a restricted mean survival time (RMST) advantage of 1.02 months. A random-effects meta-analysis of five studies confirmed this benefit (HR 0.78, 95% CI: 0.61-0.99; I2 = 75%). Pairwise analyses at 12 months demonstrated fewer AF recurrences with GLP-1 RAs (28.6% vs. 32.9%; RR 0.82, 95% CI: 0.76-0.90; I2 = 46.9%).
Conclusion: GLP-1 RA therapy was associated with reduced AF recurrence…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 695 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.